Forest Laboratories (NYSE: FRX) announced today it has agreed to settle the patent infringement lawsuit it had brought against Glenmark Generics. That litigation was in response to Glenmark's seeking approval to produce a generic version of Forest's hypertension drug, BYSTOLIC (generic name, nebivolol).
Under the terms of the agreement, Glenmark will not be allowed to produce its version of nebivolol prior to three months before Forest's patent expires.
This settlement is just one more agreement Forest has made with companies seeking to produce generic versions of BYSTOLIC. Forest made previous settlement agreements with Hetero Labs, Alkem Laboratories, Indchemie Health Specialities, and Torrent Pharmaceuticals.
Forest still has BYSTOLIC patent infringement litigation pending against Amerigen Pharmaceuticals and Watson Pharmaceuticals (AGN).
